Summary & Overview
CPT 0223U: QIAstat–Dx Respiratory SARS–CoV–2 Multiplex PCR Panel
CPT code 0223U denotes a Proprietary Laboratory Analyses (PLA) test for the QIAstat–Dx® Respiratory SARS CoV–2 Panel, an automated multiplex PCR assay run on nasopharyngeal specimens to detect common viral and bacterial respiratory pathogens including SARS–CoV–2. As a PLA code, 0223U uniquely identifies a single manufacturer's test, which supports lab-level tracking, reimbursement specificity, and clinical use monitoring nationwide. National relevance stems from continued demand for multiplex respiratory diagnostics during seasonal respiratory illness and ongoing SARS–CoV–2 surveillance.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise summary of coverage and coding context for those payers, benchmarking guidance where available, and the clinical and billing context necessary to understand how this PLA code fits into molecular diagnostic workflows. The publication outlines the service type, typical site of service, and payer coverage landscape; identifies common modifiers and coding mechanics; and highlights implications for laboratory billing, claims submission, and payer adjudication. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0223U is a Proprietary Laboratory Analyses (PLA) code for the QIAstat–Dx® Respiratory SARS CoV–2 Panel from QIAGEN Sciences. This test is an automated polymerase chain reaction (PCR) assay performed on a nasopharyngeal specimen that detects the most common viral and bacterial respiratory pathogens, including SARS–CoV–2.
Service Type: Automated PCR-based multiplex respiratory pathogen panel
Typical Site of Service: Clinical laboratory or hospital laboratory performing high-throughput molecular diagnostics
Clinical & Coding Specifications
Clinical Context
A symptomatic adult or pediatric patient presents to an outpatient clinic, urgent care, emergency department, or hospital with acute respiratory symptoms such as fever, cough, sore throat, nasal congestion, shortness of breath, or myalgias. The clinician suspects a viral or atypical bacterial respiratory infection and orders multiplex molecular testing. A nasopharyngeal swab (or other validated upper respiratory specimen) is collected and sent to the laboratory. The laboratory performs the proprietary automated PCR assay QIAstat–Dx® Respiratory SARS Co–V–2 Panel and reports results for the most common viral and bacterial respiratory pathogens, including SARS–CoV–2. Results guide infection control decisions, antiviral or antibacterial therapy considerations, patient triage, and public health reporting. Typical workflow steps: specimen collection with appropriate PPE, specimen transport to the laboratory, accessioning, running the QIAstat–Dx assay per manufacturer instructions, verification of internal controls, result interpretation, and reporting into the electronic medical record and to public health if required.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default — no modifier | Use when no other modifier applies and the full procedural service is reported |
22 | Increased procedural services | Use when substantially greater lab resources or complexity were required beyond usual test performance and documentation supports unusual effort